Fairvalue-Calculator Fairvalue-Calculator
EN DE

THOXF (THOXF) Fair Value & Analysis

Healthcare · US · Market cap $73.8M

Price$0.1490
Fair Value$0.1600
Upside+7.4%
Quality95/100
Evidence: Low Range $0.1100 – $0.2000

Fair value as of: Jun 26, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

THOXF (THOXF) currently trades at $0.1490, while our model-based Fair Value estimate is $0.1600 — implying the stock looks roughly 7.4% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the kidney injury in critically ill patients at earlier stage in Denmark, rest of Europe, North America, and Asia. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine, EDTA plasma, or heparin plasma on automated clinical chemistry analyzers to diagnose acute kidney injury; and antibodies to develop diagnostic immunoassays within disease areas, including immunodeficiency, allergy, coagulation, diabetes, kidney, and cardiovascular disease. The company also provides ready-to-use enzyme-linked immunosorbent assay (ELISA) kits to quantify NGAL in urine, plasma, and serum; and generic Rapid Assay Device (gRAD) for custom lateral flow assays. BioPorto A/S was founded in 1917 and is based in Helle…

Open the full interactive analysis →

Similar stocks

Thermo Fisher Scientific Inc (TMO) -56% Danaher Corporation (DHR) -37% WuXi AppTec Co (WUXAY) +35% IDEXX Laboratories, Inc (IDXX) -53% Lonza Group (LZAGY) -74% Agilent Technologies, Inc (A) -50%

Frequently asked questions

Is THOXF (THOXF) undervalued?
As of Jun 26, 2026, our model estimates a fair value of $0.1600 versus a price of $0.1490 — about +7% (undervalued). Model-based estimate, not financial advice.
What is the fair value of THOXF?
Our 21-model fair value for THOXF is $0.1600 (as of Jun 26, 2026), built from audited fundamentals. The current price is $0.1490.
What is the quality score of THOXF?
THOXF has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.